The blood in systemic disorders

Lancet

Volumn 355, Issue 9216, 2000, Pages 1707-1712

  Spivak, Jerry L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ACUTE KIDNEY FAILURE; ANEMIA; BONE MARROW CELL; CANCER; CELL PROLIFERATION; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; ENDOCRINE DISEASE; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LIVER DISEASE; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SYSTEMIC DISEASE;

EID: 0034643632     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02249-2     Document Type: Review

References (39)

1. Pirayesh A, Verbunt RJAM, Kluin PHM, et al. Myelodysplastic syndrome with vasculitic manifestations. J Intern Med 1997; 242: 425-31.
2. Dement SH, Eggleston JG, Spivak JL. Association between mediastinal germ cell tumors and hematologic malignancies. Am J Surg Pathol 1985; 9: 23-30.
3. Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966; 3: 351-75.
4. Cash JM, Sears DA. The anemia of chronic disease: spectrum of associated disease in a series of unselected hospitalized patients. Am J Med 1989; 87: 638-44.
5. Spivak JL, Pham T, Isaacs M, et al. Erythropoietin is both a mitogen and a survival factor. Blood 1991; 77: 1228-33.
6. Koury MJ, Bondurant MD. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248: 378-81.
7. Spivak JL. The clinical physiology of erythropoietin. Semin Hematol 1993; 30: 2-11.
8. Cazzola M, Guarnone R, Cerani P, et al. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 1998; 91: 2139-45.
9. Singh A, Eckardt KE, Zimmermann AG. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 1993; 91: 251-56.
10. Jelkman W, Pagel H, Wolff M, et al. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1991; 50: 301-08.
11. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80: 1639-47.
12. Pincus T, Olsen N, Russel IJ. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89: 161-68.
13. Schreiber S, Howaldt S, Schnoor M. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996; 334: 619-23.
14. Oster W, Herrman F, Gamm H. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 1990; 8: 956-62.
15. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990; 322: 1488-93.
16. Spivak JL, Watson AF. Hematopoiesis and the kidney. In: Seldin D, Glebisch G, eds. The kidney, 2nd edn. New York: Raven Press, 1991: 1553-93.
17. Klassen DK, Spivak JL. Hepatitis-related hepatic erythropoietin production. Am J Med 1990; 89: 684-86.
18. Eschbach JW, Abdulhadi MD, Browne JK. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000.
19. Spivak JL. Masked megaloblastic anemia. Arch Intern Med 1982; 142: 2111-14.
20. Lipkin GW, Kendall RG, Russon LH. Erythropoietin deficiency in acute renal failure. Nephrol Dial Transplant 1990; 5: 920-22.
21. Brown CH, Kvols LK, Hsu TH. Factor IX deficiency and bleeding in a patient with Sheehan's syndrome. Blood 1972; 39: 650-57.
22. Horton L, Coburn RJ, England JM. The haematology of hypothyroidism. QJM 1975; 177: 101-24.
23. Nightingale S, Vitek PJ, Himsworth RL. The haematology of hyperthyroidism. QJM 1978; 185: 35-47.
24. Dalton RG, Savidge GF, Matthews KB. Hypothyroidism as a cause of aquired von Willebrand's disease Lancet 1987; i: 1007-09.
25. Carmel R, Spencer CA. Clinical and subclinical thyroid disorders associated with pernicious anemia. Arch Intern Med 1982; 142: 1465-69.
26. Pounder RE, Craven ER, Henthorn JS. Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis. Gut 1975; 16: 181-86.
27. Siciliano M, Tomasello D, Milanti A. Reduced serum levels of immunoractive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology 1995; 22: 1132-35.
28. Savage D, Lindenbaum J. Anemia in alcoholics. Medicine 1986; 65: 322-38.
29. Eichner ER. The hematologic disorders of alcoholism. Am J Med 1973; 54: 621-30.
30. Budman DR, Steinberg AD. Hematologic aspects of systemic lupus erythematosus. Ann Intern Med 1977; 86: 220-29.
31. Asherson RA, Khamashta M, Ordi-Ros J, et al. The primary antiphospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366-74.
32. Barrett-Connor E. Anemia and infection. Am J Med 1972; 52: 242-53.
33. Perrin LH, Mackey LJ, Miescher PA. The hematology of malaria in man. Semin Hematol 1982; 19: 70-82.
34. Spivak JL. Bender BS, Quinn TC. Hematologic abnormalities in the acquired immunodeficiency syndrome. Am J Med 1984; 77: 224-28.
35. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 29-33.
36. Spivak JL, Barnes DC, Fuchs E, et al. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989; 261: 3104-07.
37. Ludwig, H, Fritz E, Leitgeb C, et al. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 1994; 84: 1056-63.
38. Sack GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine 1977; 56: 1-37.
39. Doll D, Weiss RB. Chemotherapeutic agents and the erythron. Cancer Treat Rev 1983; 10: 185-200.